Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 601–700 of 1,007
MicroRNAs in the tumor endothelium: Novel controls on the angioregulatory switchboard
Heusschen, R., van Gink, M., Griffioen, A. W., & Thijssen, V. L. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.09.005 · Cited by 73
Autophagy, a double-edged sword in anti-angiogenesis therapy
Liu, J., Fan, L., Wang, H., & Sun, G. (2015) · Medical Oncology · doi:10.1007/s12032-015-0721-9 · Cited by 75
Zanivan, S., Maione, F., Hein, M. Y., Hernández-Fernaud, J. R., Ostasiewicz, P., Giraudo, E., & Mann, M. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.031344 · Cited by 69
“Extensive work is therefore devoted to the characterization of molecular mechanisms regulating ECs in angiogenesis and to discover therapeutic targets with improved efficacy to interfere with this process [5, 6].”
BackgroundDelasoie, J., Pavić, A., Voutier, N., Vojnović, S., Crochet, A., Nikodinović‐Runić, J., & Zobi, F. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112583 · Cited by 72
Yang, X., Zhang, Y., Yang, Y., Lim, S., Cao, Z., Rak, J. W., & Cao, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309629110 · Cited by 74
Ghilardi, C., Chiorino, G., Dossi, R., Nagy, Z., Giavazzi, R., & Bani, M. R. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-201 · Cited by 69
“Background Interference with tumor vessel formation and blood supply has become a well-recognized approach of cancer therapy [1], as epitomized by the recent FDA approval of antiangiogenic drugs such as the humanized anti Vascular Endothelial Growth Factor (VEGF) antibody Avastin® [2].”
BackgroundSilva, P. N., Green, B. J., Altamentova, S. M., & Rocheleau, J. V. (2013) · Lab on a Chip · doi:10.1039/c3lc50680k · Cited by 70
Matsuo, Y., Sawai, H., Ma, J., Xu, D., Ochi, N., Yasuda, A., Takahashi, H., Funahashi, H., & Takeyama, H. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21245 · Cited by 69
PET imaging of tumor angiogenesis in mice with VEGF‐A–targeted 86Y‐CHX‐A″‐DTPA‐bevacizumab
Nayak, T. K., Garmestani, K., Baidoo, K. E., Milenic, D. E., & Brechbiel, M. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25409 · Cited by 71
“Abnormal angiogenesis, one of the hallmarks of cancer, is characterized by an increase in the number of proliferating endothelial cells and altered morphology of the vasculature resulting in increased tumor cell migration and proliferation.(1,2) The vascular endothelial growth factor (VEGF) is a proangiogenic factor t…”
BackgroundInfluentialAlvaro, D., Macarri, G., Mancino, M. G., Marzioni, M., Bragazzi, M. C., Onori, P., Corradini, S. G., Invernizzi, P., Franchitto, A., Attili, A. F., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-7-200710020-00003 · Cited by 69
“This vascular growth factor, as the main player in the neoangiogenesis process, is actively involved in the growth and spreading of different types of cancer, including cholangiocarcinoma (41, 42).”
BackgroundComputational Model of VEGF Spatial Distribution in Muscle and Pro-Angiogenic Cell Therapy
Gabhann, F. M., Ji, J. W., & Popel, A. S. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0020127 · Cited by 73
“Use of VEGF as a pro-angiogenic treatment for cardiac and limb ischemia has generated intense interest but direct administration of VEGF has not yet produced effective results in humans, and initial trials of transplantation of angiogenic cells have proven effective but require further work [16–18].”
Antiangiogenesis therapy: an update after the first decade
Falco, S. D. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.1.1 · Cited by 78
“It is unsurprising that structural alterations or functional aberrations of vessels are involved in a plethora of diseases [3,4].”
BackgroundUlahannan, S. V., & Brahmer, J. R. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.554476 · Cited by 72
Leen, E. L. S., Averkiou, M. A., Arditi, M., Burns, P. N., Bokor, D., Gauthier, T. P., Kono, Y., & Lucidarme, O. (2012) · European Radiology · doi:10.1007/s00330-011-2373-2 · Cited by 68
“[1–3].”
Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC
Hui, X., Han, Y., Liang, S., Liu, Z., Liu, J., Hong, L., Zhao, L., Li, H., Cao, S., Chen, B., et al. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.024 · Cited by 68
“So far, many angiogenic cell surface receptors/homing motifs have been found by this technology including avβ3 integrin/RGD, CD13/NGR, APA/CPRECES, MMP-2/CTTHWGFTLC, HSP90/CVPELGHEC, and others [5,27,28].”
BackgroundGourlaouen, M., Welti, J. C., Vasudev, N. S., & Reynolds, A. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446401 · Cited by 87
Ma, L., Chen, J., Wang, X., Liang, X., Luo, Y., Zhu, W., Wang, T., Peng, M., Li, S., Shi, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200830u · Cited by 68
DAVID, M., Ribeiro, J., Descôtes, F., Serre, C., BARBIER, M., Murone, M., Clézardin, P., & Peyruchaud, O. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1309 · Cited by 68
Development of withaferin A analogs as probes of angiogenesis
Yokota, Y., Bargagna‐Mohan, P., Ravindranath, P. P., Kim, K. B., & Mohan, R. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.039 · Cited by 68
Cordani, M., Pacchiana, R., Butera, G., D’Orazi, G., Scarpa, A., & Donadelli, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.046 · Cited by 76
“It is characterized by the formation of abnormal, tortuous, and poorly organized vessels with altered permeability within the tumour tissue [38, 85, 86].”
BackgroundCerezo, A. B., Ortega, R. H., Álvarez‐Fernández, M. A., Troncoso, A. M., & García-Parrilla, M. C. (2017) · Nutrients · doi:10.3390/nu9030249 · Cited by 77
“However, the mechanism of action by which melatonin exerts its direct anti-angiogenic effect on endothelial cells in the presence of VEGF, which is the most active endogenous pro-angiogenic factor, while considering the activation of VEGFR-2, the main mediator of the proliferation, migration, survival, and permeabilit…”
BackgroundFirst-Line Management of Advanced High-Grade Serous Ovarian Cancer
Mahmood, R. D., Morgan, R. D., Edmondson, R. J., Clamp, A. R., & Jayson, G. C. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00933-8 · Cited by 74
Antiangiogenic Therapy for Cancer: An Update
Shojaei, F., & Ferrara, N. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e31815a7b69 · Cited by 72
Self-citationChemopreventive Potential of Natural Compounds in Head and Neck Cancer
Rahman, M. A., Amin, A. R. M. R., & Shin, D. M. (2010) · Nutrition and Cancer · doi:10.1080/01635581.2010.509538 · Cited by 68
“EGCG interrupted angiogenesis by inhibiting phosphorylation of VEGFR (136) and inhibiting VEGF secretion by tumor cells (137).”
BackgroundInfluentialAngiocrine endothelium: from physiology to cancer
Pasquier, J., Ghiabi, P., Chouchane, L., Razzouk, K., Rafii, S., & Rafii, A. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02244-9 · Cited by 69
Lipocalin Family Proteins and Their Diverse Roles in Cardiovascular Disease
Yang, H.-H., Wang, X., Li, S.-R., Liu, Y., Akbar, R., & Fan, G. (2023) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2023.108385 · Cited by 60
Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer
Cunha, S. I., Bocci, M., Lövrot, J., Eleftheriou, N., Roswall, P., Cordero, E., Lindström, L., Bartoschek, M., Haller, B. K., Pearsall, R. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3706 · Cited by 70
Netrin-4 Delays Colorectal Cancer Carcinomatosis by Inhibiting Tumor Angiogenesis
Eveno, C., Broquères-You, D., Féron, J.-G., Rampanou, A., Tijeras‐Raballand, A., Ropert, S., Leconte, L., Levy, B. I., & Pocard, M. D. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.019 · Cited by 67
“In neoplasms, tumor-derived factors promote angiogenesis.(5) The neovascularization expands the vascular bed, causing tumor growth and a continuity with the systemic circulation; these changes provide a critical growth advantage for tumor progression and metastasis,(6,7) suggesting that targeting the tumor’s dependenc…”
BackgroundMicrovascular endowment in the developing chicken embryo lung
Makanya, A. N., Hlushchuk, R., Baum, O., Velinov, N., Ochs, M., & Djonov, V. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00371.2006 · Cited by 67
“Embryonic cardiovascular adaptation to changes in metabolic and hemodynamic demands occurs at the tissue and cellular levels; however, there are limits to adaptation that result in a normal mature phenotype (25).”
BackgroundNon-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging
Kiessling, F. M., Jugold, M., Woenne, E. C., & Brix, G. (2007) · European Radiology · doi:10.1007/s00330-006-0566-x · Cited by 67
“[14–16].”
BackgroundSinha, S., Khan, S. U., Shukla, S., Lakra, A. D., Kumar, S., Das, G., Maurya, R., & Meeran, S. M. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.014 · Cited by 67
Molecular heterogeneity of tumor endothelium
Aird, W. C. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0672-y · Cited by 66
“Ferrara and Kerbel 2005; Folkman 2007; Kerbel 2008).”
BackgroundTaylor, S. K., Chia, S., Dent, S. F., Clemons, M. J., Agulnik, M., Grenci, P., Wang, L. E., Oza, A. M., Ivy, P. S., Pritchard, K. I., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0081 · Cited by 69
Liu, X., Zhang, B., McBride, J. D., Zhou, K., Lee, K., Zhou, Y., Liu, Z., & Ma, J.-X. (2013) · Diabetes · doi:10.2337/db12-1710 · Cited by 53
“A number of natural antiangiogenic factors or angiogenic inhibitors have been identified (1).”
BackgroundFluid mechanics in circulating tumour cells: Role in metastasis and treatment strategies
Rajput, S., Sharma, P. K., & Malviya, R. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100158 · Cited by 75
The Force at the Tip - Modelling Tension and Proliferation in Sprouting Angiogenesis
Santos-Oliveira, P., Correia, A. F., Rodrigues, T., Ribeiro‐Rodrigues, T., Matafome, P. N., Rodríguez-Manzaneque, J. C., Seiça, R. M. F., Girão, H., & Travasso, R. D. M. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004436 · Cited by 70
“Currently, many cancer therapies are designed to inhibit the surrounding vasculature depriving the tumor of oxygen and nutrients, but at the same time to facilitate the delivery of chemotherapeutic drugs [8–13].”
EphrinB2 controls vessel pruning through STAT1-JNK3 signalling
Salvucci, O., Ohnuki, H., Maric, D., Hou, X., Li, X., Yoon, S. O., Segarra, M., Eberhart, C. G., Acker‐Palmer, A., & Tosato, G. (2015) · Nature Communications · doi:10.1038/ncomms7576 · Cited by 70
Regulation of endothelial cell activation and angiogenesis by injectable peptide nanofibers
Cho, H., Balaji, S., Sheikh, A. Q., Hurley, J. R., Tian, Y., Collier, J. H., Crombleholme, T. M., & Narmoneva, D. A. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.08.029 · Cited by 69
“The process of angiogenesis includes endothelial cell activation by angiogenic growth factors or changes in the extracellular environment, followed by cell migration, proliferation, formation of nascent capillaries, vasculature remodeling and maturation [30].”
The Foxc2 transcription factor regulates tumor angiogenesis
Sano, H., LeBoeuf, J. P., Novitskiy, S., Seo, S., Zaja-Milatovic, S., Dikov, M., & Kume, T. (2010) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2010.01.015 · Cited by 69
“VEGF signaling is essential for endothelial cell survival [2,3], whereas inhibition of the PDGFR-b pathway causes apoptosis in vascular endothelial cells [18,19].”
Yuen, W. W., Du, N. R., Chan, C. H., Silva, E. A., & Mooney, D. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001192107 · Cited by 70
“This hypothesis was examined in the context of VEGF-driven angiogenesis, using delivery of both recombinant human VEGFand an angiogenic inhibitor, anti-VEGF antibody (anti-VEGF) (17), and utilizing a biodegradable polymer scaffold system to allow local and sustained release of the two factors.”
MethodPeng, F., Xu, Z., Wang, J., Chen, Y., Li, Q., Zuo, Y., Chen, J., Hu, X., Zhou, Q.-C., Wang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034646 · Cited by 71
Chang, C., Hsiao, Y., Mihm, M. C., & Nelson, J. S. (2008) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20716 · Cited by 66
“Angiogenesis inhibitors have been derived from a number of sources, including cleaved proteins, monoclonal antibodies, and natural products which contain a variety of chemopreventive compounds that can prevent the development of malignancies [17].”
Developments in targeted therapy in melanoma
Amann, V. C., Ramelyte, E., Thurneysen, S., Pitocco, R., Jaberg-Bentele, N. F., Goldinger, S. M., Dummer, R., & Mangana, J. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.10.014 · Cited by 79
“The relevance of angiogenesis/neoangiogenesis in tumor 290 metabolism, proliferation and the tumor microenvironment is unquestioned (63), thus the 291 inhibition of the VEGF pathway offers a promising therapeutic approach.”
BackgroundKim, G. D. (2017) · Journal of Cancer Prevention · doi:10.15430/jcp.2017.22.4.219 · Cited by 66
“The inhibition of vascular formation holds promising anticancer potential.(2,3) Therefore, studies to elucidate the mechanisms of angiogenesis in cancer and identify novel antiangiogenic agents are warranted.”
BackgroundRole of microRNA-34 family in cancer with particular reference to cancer angiogenesis
Maroof, H., Salajegheh, A., Smith, R. A., & Lam, A. K.-Y. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.08.002 · Cited by 71
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
Wang, D., Xiao, F., Feng, Z., Li, M., Kong, L., Huang, L., Wei, Y., Li, H., Liu, F., Zhang, H., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01346-y · Cited by 74
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
Cao, Y., Zhong, W., & Sun, Y. P. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.001 · Cited by 74
Chislock, E. M., Ring, C., & Pendergast, A. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304188110 · Cited by 65
“Endothelial function is regulated, in part, by a variety of vascular growth factors, including vascular endothelial growth factor (VEGF) and the angiopoietins (Angpt) (3).”
BackgroundMethodInfluentialCristofaro, B., Stone, O. A., Caporali, A., Dawbarn, D., Ieronimakis, N. M., Reyes, M., Madeddu, P. R., Bates, D. O., & Emanueli, C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.205468 · Cited by 68
Geretti, E., & Klagsbrun, M. (2007) · Cell Adhesion & Migration · doi:10.4161/cam.1.2.4490 · Cited by 68
Girding for migratory cues: roles of the Akt substrate Girdin in cancer progression and angiogenesis
Weng, L., Enomoto, A., Takagishi, M., Asai, N., & Takahashi, M. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01487.x · Cited by 72
Diamond, J. R., Bastos, B. R., Hansen, R. J., Gustafson, D. L., Eckhardt, S. G., Kwak, E. L., Pandya, S. S., Fletcher, G. C., Pitts, T. M., Kulikowski, G. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2144 · Cited by 65
“These receptors transduce signals from pro-angiogenic factors, promoting angiogenesis (8, 9), the process by which tumors recruit their vascular supply (10).”
BackgroundExploring quercetin and luteolin derivatives as antiangiogenic agents
Ravishankar, D., Watson, K. A., Boateng, S. Y., Green, R. J., Greco, F., & Osborn, H. M. I. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.056 · Cited by 65
Optical studies of vaporization and stability of fluorescently labelled perfluorocarbon droplets
Reznik, N., Seo, M., Williams, R., Bolewska‐Pedyczak, E., Lee, M., Matsuura, N., Gariépy, J., Foster, F. S., & Burns, P. N. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/21/7205 · Cited by 65
Sheikh, A. Q., Taghian, T., Hemingway, B., Cho, H., Kogan, A. B., & Narmoneva, D. A. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0548 · Cited by 67
“factors or changes in the extracellular environment, followed by cell migration, proliferation, formation of nascent capillaries, vasculature remodelling and maturation [11].”
BackgroundCancer Stem Cells and Tumor Response to Therapy: Current Problems and Future Prospects
Milas, L., & Hittelman, W. N. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.11.004 · Cited by 77
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
Shao, R., Taylor, S. L., Oh, D. S., & Schwartz, L. M. (2015) · Oncotarget · doi:10.18632/oncotarget.5943 · Cited by 71
“As reviewed in a number of previous publications, most of clinical trials exploiting these agents have provided encouraging results such as increased progression-free survival in patients (Table 1) [3, 77-80].”
ResultTargeted multidrug delivery system to overcome chemoresistance in breast cancer
Tang, Y., Soroush, F., Tong, Z., Kiani, M. F., & Wang, B. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s124770 · Cited by 65
Mesoporous Silica Nanoparticles as an Antitumoral-Angiogenesis Strategy
Setyawati, M. I., & Leong, D. T. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b12524 · Cited by 65
Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate
Binz, H. K., Bakker, T. R., Phillips, D. J., Cornelius, A., Zitt, C., Göttler, T., Sigrist, G., Fiedler, U., Ekawardhani, S., Dolado, I., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1305529 · Cited by 76
Han, X., Zhang, X., Wang, Q., Wang, L., & Yu, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110735 · Cited by 66
Lee, S., Kim, S., Koo, D.-J., Yu, J., Cho, H., Lee, H., Song, J. M., Kim, S., Min, D., & Jeon, N. L. (2020) · ACS Nano · doi:10.1021/acsnano.0c05110 · Cited by 68
Shu, X., Zhan, P., Sun, L., Yu, L., Liu, J., Sun, L., Yang, Z., Ran, Y., & Sun, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.659260 · Cited by 70
“In recent years, antiangiogenesis has become a promising strategy for tumor therapy (Ferrara and Kerbel, 2005).”
BackgroundBashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saad, A., & Noureddin, B. N. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.02.006 · Cited by 75
Carneiro, Â. M., Barthelmes, D., Falcão, M. S., Mendonça, L. S., Fonseca, S. L., Gonçalves, R. M., Faria-Correia, F., & Falcão‐Reis, F. (2011) · Ophthalmologica · doi:10.1159/000323943 · Cited by 71
“Vascular endothelial growth factor A (VEGF-A) is a crucial proangiogenic factor involved in the pathogenesis of exudative AMD (exAMD) [”
BackgroundFujii, H., Shin‐Ya, M., Takeda, S., Hashimoto, Y., Mukai, S., Sawada, S., Adachi, T., Akiyoshi, K., Miki, T., & Mazda, O. (2014) · Cancer Science · doi:10.1111/cas.12547 · Cited by 65
Wang, L., Chen, G., Lu, X., Wang, S., Han, S., Li, Y., Ping, G., Jiang, X., Li, H., Yang, J., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.036 · Cited by 64
Vasculogenic Cytokines in Wound Healing
Wong, V., & Crawford, J. D. (2013) · BioMed Research International · doi:10.1155/2013/190486 · Cited by 73
“Conversely, dysregulated signaling can promote tumor growth and metastasis [10, 11].”
BackgroundRecent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Bai, M., & Bornhop, D. J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803341467 · Cited by 64
“Similar to integrin receptors, VEGF receptors are also involved in regulation of tumor angiogenesis, therefore can be potentially targeted for cancer imaging [148].”
BackgroundLankhorst, S., Kappers, M. H. W., van Esch, J. H. M., Danser, A. H. J., & van den Meiracker, A. H. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835c1d1b · Cited by 76
“VEGF is upregulated by hypoxia-inducible factor (HIF) 1a and several other factors [2,16].”
BackgroundXuan, J. W., Bygrave, M., Jiang, H., Valiyeva, F., Dunmore‐Buyze, J., Holdsworth, D. W., Izawa, J. I., Bauman, G. S., Moussa, M., Winter, S. F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3944 · Cited by 65
Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo
Nakayama, H., Bruneau, S., Kochupurakkal, N. M., Coma, S., Briscoe, D. M., & Klagsbrun, M. (2015) · Scientific Reports · doi:10.1038/srep11789 · Cited by 70
Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise
Ji, J. W., Gabhann, F. M., & Popel, A. S. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00009.2007 · Cited by 73
“In PAD, delivery of VEGF via bolus injection, adeno-associated viral vector, or transplantation of proangiogenic cells has shown great therapeutic potential by increasing blood perfusion and tissue oxygenation, but each mode of delivery requires further investigations to confirm its effectiveness and safety (9, 19, 56…”
BackgroundHosono, K., Suzuki, T., Tamaki, H., Sakagami, H., Hayashi, I., Narumiya, S., Alitalo, K. K., & Majima, M. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.222356 · Cited by 65
Korsisaari, N., Kasman, I. M., Forrest, W. F., Pal, N., Bai, W., Fuh, G., Peale, F. V., Jr., Smits, R., & Ferrara, N. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704213104 · Cited by 65
Self-citationRepurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
Ma, Z., Woon, C. Y.-N., Liu, C., Cheng, J.-T., You, M., Sethi, G., Wong, A. L., Ho, P. C., Zhang, D., Ong, P.-S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.828856 · Cited by 69
“Cancer type Cell line IC50 value (µM) Mechanism of action Ref 24H 48H 72H Artemisinin Gall bladder Cancer GBC-SD — 49.1 ± 1.69 — Upregulate p16, downregulate CDK4 and cyclin D1 to induce G1-phase cell cycle arrest Jia et al. (2016a) NOZ — 58.6 ± 1.77 — Activate caspase-3 to induce apoptosis Induce Δψm collapse of via…”
BackgroundInfluentialNanoparticle-Mediated Delivery of shRNA.VEGF-A Plasmids Regresses Corneal Neovascularization
Qazi, Y., Stagg, B. C., Singh, N., Singh, S. R., Zhang, X., Luo, L., Simonis, J. M., Kompella, U. B., & Ambati, B. K. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-9139 · Cited by 64
Szot, C. S., Buchanan, C. F., Freeman, J. W., & Rylander, M. N. (2013) · Tissue Engineering Part C: Methods · doi:10.1089/ten.tec.2012.0684 · Cited by 63
Therapeutic manipulation of angiogenesis with miR-27b
Veliceasa, D., Biyashev, D., Qin, G., Misener, S., Mackie, A. R., Kishore, R., & Volpert, O. V. (2015) · Vascular Cell · doi:10.1186/s13221-015-0031-1 · Cited by 69
Endocannabinoid system modulation in cancer biology and therapy.
Pisanti, S., & Bifulco, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.011 · Cited by 66
“As proposed in 1971 by Folkman, tumor growth and metastais formation are angiogenesis-dependent processes and hence, locking angiogenesis is turned out to be a fundamental theraeutic strategy to arrest tumor growth [34].”
BackgroundZhang, E., Shi, H., Yang, L., Wu, X., & Wang, Z. (2017) · Oncology Reports · doi:10.3892/or.2017.5652 · Cited by 65
Mesquita, J., Sousa, J. P. C., Vaz-Pereira, S., Neves, A., Passarinha, L. A., & Tomaz, C. T. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.11.005 · Cited by 69
Hasina, R., Martin, L. E., Kasza, K., Jones, C. L., Jalil, A., & Lingen, M. W. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0211 · Cited by 63
“The integration of inhibitors of angiogenesis into the treatment regimens of various diseases is increasing in frequency (47, 48).”
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
Lu‐Emerson, C., Norden, A. D., Drappatz, J., Lee, E. Q., Beroukhim, R., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Ruland, S. F., & Wen, P. Y. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0489-x · Cited by 66
“The Food and Drug Administration (FDA) recently granted accelerated approval for bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), for the treatment of recurrent GBM [9–11].”
BackgroundVascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma
Albiges, L. K., Salem, M. E., Rini, B. I., & Escudier, B. J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.006 · Cited by 62
Anti-Angiogenic Therapeutic Drugs for Treatment of Human Cancer
Wu, H., Huang, C.-T., & Chang, D.-K. (2008) · Cited by 67
Anti‐VEGF DNA‐based aptamers in cancer therapeutics and diagnostics
Riccardi, C., Napolitano, E., Platella, C., Musumeci, D., Melone, M. A. B., & Montesarchio, D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21737 · Cited by 67
Leal, P. F., Kfouri, M. B., Alexandre, F. C., Fagundes, F. H. R., Prado, J. M., Toyama, M. H., & Meireles, M. A. A. (2010) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2010.03.007 · Cited by 62
Inhibition of angiogenesis and invasion in malignant gliomas
Chi, A. S., Norden, A. D., & Wen, P. Y. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.11.1537 · Cited by 64
Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1α inhibitors
Shimizu, K., Maruyama, M., Yasui, Y., Minegishi, H., Ban, H. S., & Nakamura, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.037 · Cited by 66
Becker, R., Lenter, M., Vollkommer, T., Boos, A. M., Pfaff, D., Augustin, H. G., & Christian, S. (2008) · The FASEB Journal · doi:10.1096/fj.07-101386 · Cited by 62
“Tumor blood vessels differ structurally and functionally from normal blood vessels, a characteristic that is extensively explored as a novel antitumor therapy ( 1 , 2). Endosialin was originally described as the antigen recognized by mAb FB5 as a highly specific marker of tumor blood vessels.”
BackgroundTaylor, S. M., Nevis, K. R., Park, H. L., Rogers, G. C., Rogers, S. L., Cook, J. G., & Bautch, V. L. (2010) · Blood · doi:10.1182/blood-2010-01-266197 · Cited by 63
Overcoming Resistance to Antiangiogenic Therapies
Tejpar, S., Prenen, H., & Mazzone, M. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0068 · Cited by 67
“At present, the optimal timing and dosing of antiangiogenic treatment for a given tumor, combination therapy, or patient remains unknown [2].”
InfluentialMolecular Mechanisms and Therapeutic Development of Angiogenesis Inhibitors
Cao, Y. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00004-3 · Cited by 67
Alghanem, A. F., Wilkinson, E. L., Emmett, M. S., Aljasir, M. A., Holmes, K., Rothermel, B. A., Simms, V. A., Heath, V. L., & Cross, M. J. (2017) · Angiogenesis · doi:10.1007/s10456-017-9542-0 · Cited by 62
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo
Tammali, R., Reddy, A. B. M., Srivastava, S. K., & Ramana, K. V. (2011) · Angiogenesis · doi:10.1007/s10456-011-9206-4 · Cited by 63
“Angiogenesis involves endothelial cell survival, invasion, proliferation, migration and differentiation [1–4].”
Perspicace, E., Jouan–Hureaux, V., Ragno, R., Ballante, F., Sartini, S., Motta, C. L., Settimo, F. D., Chen, B., Kirsch, G., Schneider, S., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.022 · Cited by 63
Wu, L. J., Huang, Z., Qin, P., Yao, Y., Meng, X., Zou, J., Zhu, K., & Ren, G. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf2015528 · Cited by 63
Duong, H. T., COMHAIR, S. A. A., Aldred, M. A., Mavrakis, L. A., Savasky, B. M., ERZURUM, S. C., & Asosingh, K. (2011) · Pulmonary Circulation · doi:10.4103/2045-8932.93547 · Cited by 61
“They express CD31, vWF, cav-1, eNOS, and CD34, consistent with the expression pattern expected of endothelial cells and corroborating previous reports on ECFC surface marker expression.[8,9] Staining of PAEC cultures prior to ECFC sorting also demonstrated expression of these markers (Fig.”
BackgroundResult
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.